Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAS2R14 | Q9NYV8 | 10/20 | 0.70 |
| ▸ | MEP1B | Q16820 | 1/20 | 0.61 |
| ▸ | BMP1 | P13497 | 2/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.59 |
| ▸ | CXCR3 | P49682 | 2/20 | 0.58 |
| ▸ | PTGES | O14684 | 1/20 | 0.58 |
| ▸ | TAS2R8 | Q9NYW2 | 1/20 | 0.58 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.57 |
| ▸ | MMP3 | P08254 | 1/20 | 0.56 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2513975 | 0.85 | MEP1B (0.56) | TAS2R14MEP1BBMP1ALDH1A1CXCR3 | |
| SCHEMBL7350174 | 0.84 | ALDH1A1 (0.81) | TAS2R14MEP1BBMP1ALDH1A1CXCR3 | |
| SCHEMBL2516194 | 0.83 | BMP1 (0.55) | TAS2R14MEP1BBMP1ALDH1A1CXCR3 | |
| SCHEMBL1278748 | 0.82 | TAS2R14 (1.00) | TAS2R14MEP1BCXCR3PTGESTAS2R8 | |
| SCHEMBL7348906 | 0.82 | MEP1B (0.86) | TAS2R14MEP1BBMP1CXCR3PTGES | |
| SCHEMBL27083378 | 0.81 | TAS2R14 (0.72) | TAS2R14ALDH1A1CXCR3PTGESTAS2R8 | |
| SCHEMBL8008261 | 0.79 | ALDH1A1 (0.73) | TAS2R14MEP1BBMP1ALDH1A1CXCR3 | |
| SCHEMBL4540959 | 0.79 | MEN1 (0.64) | TAS2R14BMP1ALDH1A1CXCR3PTGES | |
| SCHEMBL5093686 | 0.78 | ALDH1A1 (0.72) | TAS2R14MEP1BBMP1ALDH1A1CXCR3 | |
| SCHEMBL6411677 | 0.78 | MEP1B (0.79) | TAS2R14MEP1BBMP1MMP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8034810-B2 | Matrix metalloproteinase inhibitors; antiinflammatory agengs; rheumatoid arthritis, osteoarthritis; antitumor, anticarcinogenic, and antimetastasis agents; respiratory system disorders, chronic obstructive pulmonary disease, deblocking, deprotecting | NOVARTIS AG (CH) | 2011-10-11 | — | — | US | disclosed |
| EP-1202961-B1 | ARYLSULFONAMIDO-SUBSTITUTED HYDROXAMIC ACID DERIVATIVES | NOVARTIS AG (CH) | 2010-01-20 | — | — | EP | disclosed |
| EP-2085379-A1 | Arylsulfonamido-substituted hydroxamic acid derivatives | Novartis AG (CH) | 2009-08-05 | — | — | EP | disclosed |
| US-20080275127-A1 | Arylsulfonamido-substituted hydroxamic acid derivatives | BREITENSTEIN WERNER | 2008-11-06 | — | — | US | disclosed |
| US-7138432-B1 | Arylsulfonamido-substituted hydroxamic acid derivatives | NOVARTIS AG (CH) | 2006-11-21 | — | — | US | disclosed |
| EP-1202961-A1 | ARYLSULFONAMIDO-SUBSTITUTED HYDROXAMIC ACID DERIVATIVES | Novartis AG (CH) | 2002-05-08 | — | — | EP | disclosed |
| WO-2001010827-A1 | ARYLSULFONAMIDO-SUBSTITUTED HYDROXAMIC ACID DERIVATIVES | NOVARTIS AG (CH) | 2001-02-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080275127-A1 | Arylsulfonamido-substituted hydroxamic acid derivatives | MMP13, MMP2, MMP1 | TAS2R14 4553/4885MEP1B 2688/4885BMP1 1886/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.